Vitamin B5 may be the key to treating a dangerous rare genetic condition, according to new Concordia research

A simple vitamin could successfully treat a rare but potentially fatal genetic disease, according to new research led by a Concordia undergraduate student.

In a paper published in the Journal of Inherited Metabolic Disease, the authors describe how vitamin B5 can mitigate the life-altering and life-threatening effects related to mutations in the Transport and Golgi Organization 2 (TANGO2) gene in Drosophila melanogaster—fruit flies.

Flies with the mutation exhibited symptoms commonly associated with TANGO2 deficiency disease (TDD): they died of starvation almost twice as fast as those without it, had difficulties moving and learning and had a neuromuscular defect that manifested as spasms when exposed to high temperatures. However, when flies with the mutation were supplemented with vitamin B5, these symptoms quickly improved or, in some cases, disappeared.

“TDD is a very rare disease, but some clinicians noticed that phenotypes in patients with TDD resembled phenotypes in individuals who can’t metabolize lipids very well,” says Michael Sacher, a professor from the Department of Biology in the Faculty of Arts and Science and the paper’s supervising author.

Lipids are fatty compounds that perform several important functions, including moving and storing energy and producing hormones. They are generally activated by bonding with the coenzyme A molecule, which needs vitamin B5 to be produced.

“Since TDD is a lipid metabolism problem, we thought that if we just boosted production of coenzyme A, we would see some sort of effect on the fruit flies,” Sacher continues. “And that was exactly the case.”

Clear and rapid improvements

The paper’s lead author is Paria Asadi, who expects to complete her BSc in fall 2023. She designed and conducted a series of assays to record the differences between control and experimental groups of fruit flies.

Asadi first studied the behaviour of fruit flies with the mutation and noticed phenotypes consistent with TDD seen in humans: they died 50 per cent faster if deprived of food, suggesting a metabolic defect; they exhibited ataxia, a neurodegenerative condition characterized by poor muscle control and abnormal movements, among other symptoms; they exhibited intellectual deficits during a learning assay, in which the flies were slower to avoid exposure to the bitter taste of quinine than those without; and they were more susceptible to seizures when exposed to higher temperatures.

She then repeated these experiments on another line of fruit flies with the TDD mutation but with vitamin B5 added to their food. The results were not only remarkable — they were also quick.

“We saw that they had improved, in some cases to wild levels,” she says. “They did not have a very significant learning deficit or metabolic crises after starving. This shows that vitamin B5 can potentially be therapeutic for TDD patients.”

Other types of B vitamins were also used in tests, but none led to rescues as pronounced as B5.

Any exposure is good exposure

The researchers noticed degrees of improvement even after a very short exposure to vitamin B5. The longer the exposure, however, the more marked those improvements were.

“We were seeing a time-dependent rescue,” Sacher says. “Presumably, that would hold for humans as well. Even if a neurodevelopmental delay has occurred, which unfortunately happens to children, we can at least try to prevent a potentially fatal metabolic crisis.”

Asadi recalls presenting these findings at a TDD family conference in summer 2022 where she had a chance to talk to families affected by the disease.

“One of the mothers told me that since her child started taking multivitamins their lives had changed for the better. Just knowing how meaningful the research we are doing is for the lives of affected families was a turning point in my life,” she shares. “It made me realize how biological research at the molecular level can be impactful for so many people.”

Concordia researchers Miroslav Milev and Djenann Saint-Dic and former Concordian Chiara Gamberi, now at Coastal Carolina University in the United States, co-authored the paper.

The study was supported by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada (NSERC), the TANGO2 Research Foundation, the National Institute of Health [AF1] [PL2] and the IDeA Network for Biomedical Research Excellence.

Read the cited paper: “Vitamin B5, a coenzyme A precursor, rescues TANGO2 deficiency disease-associated defects in Drosophila and human cells.